L. Inhibiteurs-de-l-'aromatase and .. , 20 L'aromatase: structure et mode d'action, p.20

.. Au-tamoxifène, Résumé des études en phase adjuvante des inhibiteurs de l'aromatase en comparaison, p.28

K. Agrawal, Cognitive changes associated with endocrine therapy for breast cancer, Maturitas, vol.67, issue.3, 2010.
DOI : 10.1016/j.maturitas.2010.07.004

P. Ahn, H. Vu, and D. Lannin, Sequence of Radiotherapy With Tamoxifen in Conservatively Managed Breast Cancer Does Not Affect Local Relapse Rates, Journal of Clinical Oncology, vol.23, issue.1, pp.17-23, 2005.
DOI : 10.1200/JCO.2005.09.048

H. Allemand, B. Seradour, A. Weill, and P. Ricordeau, Baisse de l'incidence des cancers du sein en 2005-2006 en France: un phénomène paradoxal, Bull Cancer, vol.95, pp.11-15, 2008.

B. Allen and E. Doisy, AN OVARIAN HORMONE, Journal of the American Medical Association, vol.81, issue.10, pp.819-821, 1923.
DOI : 10.1001/jama.1923.02650100027012

M. Alonso-muñoz, M. Ojeda-gonzáles, and . Beltran-fabregat, Randomized Trial of Tamoxifen versus Aminoglutethimide and versus Combined Tamoxifen and Aminoglutethimide in Advanced Postmenopausal Breast Cancer, Oncology, vol.45, issue.5, pp.350-353, 1988.
DOI : 10.1159/000226639

G. Anker, P. Lonning, P. Ueland, H. Refsum, and E. Lien, Plasma levels of the atherogenic amino acid homocysteine in postmenopausal women with breast cancer treated with tamoxifen, International Journal of Cancer, vol.15, issue.3, pp.365-368, 1995.
DOI : 10.1111/j.1399-0004.1991.tb03053.x

G. Atalay, L. Dirix, and L. Biganzoli, The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients', Annals of Oncology, vol.15, issue.2, pp.211-217, 2004.
DOI : 10.1093/annonc/mdh064

H. Atkins, Adrenalectomy and hypophysectomy for advanced cancer of the breast, Lancet, vol.1, pp.1148-1153, 1960.

H. Atkins, Carcinoma of the Breast, BMJ, vol.1, issue.4819, pp.133-153, 1966.
DOI : 10.1136/bmj.1.4819.1099

P. Auvray, F. Bichat, and P. Genne, Evaluation préclinique de l'activité antitumorale des inhibiteurs de l'aromatase, Bull Cancer, vol.87, pp.1-16, 2000.

M. Baum, A. Buzdar, and J. Cuzick, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with earlystage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination), Cancer, vol.98, pp.1802-1810, 2003.

M. Baum, A. Buzdar, and J. Cuzick, Anastrozole alone or in combiation with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial, Lancet, vol.359, pp.2131-2139, 2002.

G. Beatson, On the treatment of inoperable cases of carcinoma of the mamma: suggestion for a new method of treatment with illustrative cases, Lancet, vol.2, pp.104-107, 1896.

A. Belot, P. Grosclaude, and N. Bossard, Cancer incidence and mortality in France over the period 1980???2005, Revue d'??pid??miologie et de Sant?? Publique, vol.56, issue.3, pp.159-175, 2008.
DOI : 10.1016/j.respe.2008.03.117

URL : https://hal.archives-ouvertes.fr/inserm-00338335

L. Bergman, M. Beelen, and M. Gallee, Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centers'ALERT Group

F. Boccardo, A. Rubagotti, and P. Guglielminin, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial, Annals of Oncology, vol.17, issue.suppl_7, pp.10-14, 2006.
DOI : 10.1093/annonc/mdl941

F. Boccardo, A. Rubagotti, and M. Puntoni, Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial, Journal of Clinical Oncology, vol.23, issue.22, pp.5138-5147, 2005.
DOI : 10.1200/JCO.2005.04.120

F. Bonnetain, Qualit?? de vie relative ?? la sant?? et crit??res de jugement en canc??rologie, Cancer/Radioth??rapie, vol.14, issue.6-7
DOI : 10.1016/j.canrad.2010.06.001

S. Boyd, OOPHORECTOMY IN CANCER OF THE BREAST, BMJ, vol.1, issue.2141, pp.1161-1167, 1900.
DOI : 10.1136/bmj.1.2141.110-b

B. Bradbury, T. Lash, J. Kaye, and S. Jick, Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina, Cancer, vol.287, issue.6, pp.1114-1121, 2005.
DOI : 10.1038/bjc.1998.376

R. Braithwaite, R. Chlebowski, and J. Lau, Meta-analysis of vascular and neoplastic events associated with tamoxifen, Journal of General Internal Medicine, vol.287, issue.11, pp.937-947, 2003.
DOI : 10.1001/jama.287.7.847

K. Briot and C. Roux, Musculoskeletal complications of hormonal deprivation therapies

K. Briot, M. Tubiana-hulin, L. Bastit, I. Kloos, and C. Roux, Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study, Breast Cancer Research and Treatment, vol.42, issue.8 Suppl, pp.127-134, 1996.
DOI : 10.1200/JCO.2006.05.9113

URL : https://hal.archives-ouvertes.fr/hal-00535427

C. Bushnell and L. Goldstein, Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis, Neurology, vol.63, issue.7, pp.1230-1233, 2004.
DOI : 10.1212/01.WNL.0000140491.54664.50

A. Buzdar, A. Howell, and J. Cuzick, Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial, Lancet Oncol, vol.7, pp.633-643, 2006.

A. Buzdar, J. Carpenter, M. Andrykowski, and M. Cordova, Clinical features of joint symptoms observed in the Arimidex-Tamoxifenalone or in combination (ATAC) trial Hot flashes in postmenopausal women treated for breast carcinoma: prevalence, severity, correlates, management and relation to quality of life, J Clin Oncol Cancer, vol.2482, pp.551-271682, 1998.

J. Carpenter, J. Elam, and S. Ridner, Sleep, Fatigue, and Depressive Symptoms in Breast Cancer Survivors and Matched Healthy Women Experiencing Hot Flashes, Oncology Nursing Forum, vol.31, issue.3, pp.591-598, 2004.
DOI : 10.1188/04.ONF.591-598

D. Cella, L. Fallowfield, and P. Barker, Quality of Life of Postmenopausal Women in the ATAC (???Arimidex???, Tamoxifen, Alone or in Combination) Trial after Completion of 5??years' Adjuvant Treatment for Early Breast Cancer, Breast Cancer Research and Treatment, vol.23, issue.3, pp.273-284, 2006.
DOI : 10.1007/978-3-642-55647-0_9

A. Chien and P. Goss, Aromatase Inhibitors and Bone Health in Women With Breast Cancer, Journal of Clinical Oncology, vol.24, issue.33, pp.5305-5312, 2006.
DOI : 10.1200/JCO.2006.07.5382

R. Chlebowski, J. Cuzick, and D. Amakye, Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer, The Breast, vol.18, pp.1-11, 2009.
DOI : 10.1016/S0960-9776(09)70002-5

A. Coates, A. Keshaviah, and B. Thürlimann, Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98, Journal of Clinical Oncology, vol.25, issue.5, pp.486-492, 2007.
DOI : 10.1200/JCO.2006.08.8617

N. Col, J. Guthrie, M. Politi, and L. Dennerstein, Duration of vasomotor symptoms in middle-aged women, Menopause, vol.16, issue.3, pp.453-457, 2009.
DOI : 10.1097/gme.0b013e31818d414e

M. Cole, C. Jones, and I. Todd, A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474, British Journal of Cancer, vol.25, issue.2, pp.270-275, 1971.
DOI : 10.1038/bjc.1971.33

R. Coleman, L. Banks, and S. Girgis, Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study, The Lancet Oncology, vol.8, issue.2, pp.119-127, 2007.
DOI : 10.1016/S1470-2045(07)70003-7

R. Coleman, W. Bolten, and M. Landsown, Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations, Cancer Treatment Reviews, vol.34, issue.3, pp.275-282, 2008.
DOI : 10.1016/j.ctrv.2007.10.004

R. Coombes, E. Hall, and L. Gibson, A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer, New England Journal of Medicine, vol.350, issue.11
DOI : 10.1056/NEJMoa040331

R. Coombes, L. Kilburn, and C. Snowdon, Survival and safety of exemestane versus tamoxifen after 2???3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, The Lancet, vol.369, issue.9561, pp.559-570, 2007.
DOI : 10.1016/S0140-6736(07)60200-1

K. Crew, H. Greenlee, and J. Capodice, Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer, Journal of Clinical Oncology, vol.25, issue.25, pp.3877-3883, 2007.
DOI : 10.1200/JCO.2007.10.7573

J. Cuzick, I. Sestak, D. Cella, L. Fallowfield, and . Atac-trialists-'group, Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial, The Lancet Oncology, vol.9, issue.12, pp.1143-1148, 2008.
DOI : 10.1016/S1470-2045(08)70259-6

D. Courmelles, La radiothérapie combinée du sein et des ovaires contre les tumeurs du sein. Comptes Rendus de l, Académie des Sciences, vol.174, p.503, 1922.

D. Cremoux and P. , Aromatase inhibitors: pharmacological aspects, Bull Cancer, vol.87, pp.23-29, 2000.

S. Deitcher and M. Gomes, The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma, Cancer, vol.101, issue.3, pp.439-449, 2004.
DOI : 10.1002/cncr.20347

D. Mastro, L. Dozin, B. Aitini, and E. , Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group, Annals of Oncology, vol.19, issue.2, pp.299-307, 2008.
DOI : 10.1093/annonc/mdm475

T. Delozier, O. Switsers, and J. Genot, Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial), Annals of Oncology, vol.11, issue.5, pp.515-519, 2000.
DOI : 10.1023/A:1008321415065

C. Derzko, S. Elliott, and W. Lam, Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy, Curr Oncol, vol.14, pp.20-40, 2007.

H. Ding and T. Field, Bone health in postmenopausal women with early breast cancer: How protective is tamoxifen?, Cancer Treatment Reviews, vol.33, issue.6, pp.506-513, 2007.
DOI : 10.1016/j.ctrv.2007.04.005

M. Dowsett, B. Cantwell, A. Lal, S. Jeffcoate, and A. Harris, Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormon agonist goserelin

M. Dowsett, J. Cuzick, and J. Ingle, Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen, Journal of Clinical Oncology, vol.28, issue.3, pp.509-518, 2010.
DOI : 10.1200/JCO.2009.23.1274

S. Duffy, T. Jackson, M. Lansdown, A. The, A. Dutta et al., Alone or in Combination)adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment Synthesis and biological activity of alphaazapeptides: alpha-aza-analogues of luteinizing hormone releasing hormone Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women Early Breast Cancer Trialists'Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Hum Reprod Clin Endocrinol Lancet Lancet, vol.215339339, pp.545-553, 1976.

C. Early-breast, . Trialists-'collaborative, and . Group, Tamoxifen for early breast cancer: an overview of the randomised trials Early Breast Cancer Trialists'Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women 56. Early Breast Cancer Trialists'Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet N Engl J Med Lancet, vol.351319365, pp.1451-1467, 1988.

R. Eastell, J. Adams, and R. Coleman, Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230, Journal of Clinical Oncology, vol.26, issue.7, pp.1051-1057, 2008.
DOI : 10.1200/JCO.2007.11.0726

M. Ellis, Y. Tao, and J. Luo, Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics, JNCI Journal of the National Cancer Institute, vol.10, issue.1, pp.1380-1388, 2008.
DOI : 10.1158/1078-0432.CCR-031202

L. Fallowfield, J. Bliss, and L. Porter, Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer, Journal of Clinical Oncology, vol.24, issue.6, pp.910-917, 2006.
DOI : 10.1200/JCO.2005.03.3654

D. Felson and S. Cummings, Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation, Arthritis & Rheumatism, vol.26, issue.9, pp.2594-2598, 2005.
DOI : 10.1001/jama.1925.02660280001001

J. Ferlay, H. Shin, F. Bray, D. Forman, C. Mathers et al., Estimates of worldwide burden of cancer, Int J Cancer, vol.17, 2008.

B. Fisher, J. Constantino, and D. Wickerham, Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, JNCI: Journal of the National Cancer Institute, vol.97, issue.22, pp.1652-1662, 2005.
DOI : 10.1016/j.ejca.2004.10.020

B. Fisher, J. Dignam, J. Bryant, and N. Wolmark, Five Versus More Than Five Years of Tamoxifen for Lymph Node-Negative Breast Cancer: Updated Findings From the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial, JNCI Journal of the National Cancer Institute, vol.351, issue.9114, pp.684-690, 2001.
DOI : 10.1016/S0140-6736(97)11423-4

J. Forbes, J. Cuzick, and A. Buzdar, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC, Lancet Oncol, vol.9, pp.45-53, 2008.

J. Geisler, B. Haynes, M. Dowsett, and P. Lonning, Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over Study, Journal of Clinical Oncology, vol.20, issue.3, pp.751-757, 2002.
DOI : 10.1200/JCO.2002.20.3.751

J. Geisler, N. King, and G. Anker, In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients, Clin Cancer Res, vol.4, pp.2089-2093, 1998.

P. Goss, J. Ingle, and S. Martino, A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer, New England Journal of Medicine, vol.349, issue.19, pp.1793-1802, 2003.
DOI : 10.1056/NEJMoa032312

P. Goss, J. Ingle, and S. Martino, Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17, JNCI: Journal of the National Cancer Institute, vol.97, issue.17, pp.1262-1271, 2005.
DOI : 10.1200/JCO.2005.09.121

P. Goss, H. Muss, J. Ingle, T. Whelan, and M. Wu, Extended Adjuvant Endocrine Therapy in Breast Cancer: Current Status and Future Directions, Clinical Breast Cancer, vol.8, issue.5, pp.411-417, 2008.
DOI : 10.3816/CBC.2008.n.049

S. Guerin and C. Hill, L'épidémiologie des cancers en France en 2010: comparaison avec les Etats-Unis, Bull Cancer, vol.97, pp.47-54, 2010.

V. Guetta, R. Lush, W. Figg, M. Waclawiw, and R. Cannon, Effects of the antiestrogen tamoxiten on low-density lipoprotein concentrations and oxidation in postmenopausal women, The American Journal of Cardiology, vol.76, issue.14, pp.1072-1073, 1995.
DOI : 10.1016/S0002-9149(99)80302-6

A. Haddow, J. Watinkson, and E. Paterson, Influence of Synthetic Oestrogens on Advanced Malignant Disease, BMJ, vol.2, issue.4368, pp.393-398, 1944.
DOI : 10.1136/bmj.2.4368.393

P. Hadji, Menopausal symptoms and adjuvant therapy-associated adverse events, Endocrine Related Cancer, vol.15, issue.1
DOI : 10.1677/ERC-07-0193

URL : http://erc.endocrinology-journals.org/content/15/1/73.full.pdf

P. Hadji, J. Body, and M. Aapro, Practical guidance for the management of aromatase inhibitor-associated bone loss, Annals of Oncology, vol.100, issue.20, pp.1407-1416, 2008.
DOI : 10.1001/jama.298.20.2389

D. Hadjidakis and I. Androulakis, Bone Remodeling, Annals of the New York Academy of Sciences, vol.1445, issue.3, pp.385-396, 2006.
DOI : 10.1172/JCI24918

A. Hamilton and M. Piccart, The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer, Annals of Oncology, vol.10, issue.4, pp.377-384, 1999.
DOI : 10.1023/A:1008368300827

J. Hayward, Cancer of the breast. Treatment of the advances disease, Br Med J, vol.1, pp.469-471, 1970.

N. Henry, J. Giles, and M. Mohan, Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors, Breast Cancer Research and Treatment, vol.101, issue.2, pp.365-372, 2008.
DOI : 10.1016/S0015-0282(16)55701-X

C. Herold and K. Blackwell, The impact of adjuvant endocrine therapy on reducing the risk of distant metastases in hormone-responsive breast cancer, The Breast, vol.17, pp.15-24, 2008.
DOI : 10.1016/S0960-9776(08)70004-3

W. Hoogendoorn, H. Hollema, and H. Van-boven, Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer, Breast Cancer Research and Treatment, vol.361, issue.1, pp.99-108, 2008.
DOI : 10.1136/jcp.55.7.514

K. Horwitz and W. Mcguire, Specific progesterone receptors in human breast cancer, Steroids, vol.25, issue.4, pp.497-505, 1975.
DOI : 10.1016/0039-128X(75)90027-6

A. Howell, J. Cuzick, and M. Baum, of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer, Lancet, vol.365, pp.60-62, 2005.

S. Hughes and . Aminogluthetimide, A "side effect

J. Ingle, D. Ahmann, and S. Green, Randomized Clinical Trial of Diethylstilbestrol versus Tamoxifen in Postmenopausal Women with Advanced Breast Cancer, New England Journal of Medicine, vol.304, issue.1, pp.16-21, 1981.
DOI : 10.1056/NEJM198101013040104

R. Jakesz, R. Greil, and M. Gnant, Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a, JNCI Journal of the National Cancer Institute, vol.369, issue.9561, pp.1845-1853, 2007.
DOI : 10.1016/S0140-6736(07)60200-1

R. Jakesz, W. Jonat, and M. Gnant, Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, The Lancet, vol.366, issue.9484, pp.455-462, 2005.
DOI : 10.1016/S0140-6736(05)67059-6

E. Jensen, G. Block, S. Smith, K. Kyser, and E. Desombre, Estrogen receptors and breast cancer response to adrenalectomy, Natl Cancer Inst Monogr, vol.34, pp.55-70, 1971.

W. Jonat, M. Gnant, and F. Boccardo, Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis, The Lancet Oncology, vol.7, issue.12, pp.991-996, 2006.
DOI : 10.1016/S1470-2045(06)70948-2

S. Jones, M. Savin, and F. Holmes, Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer, Journal of Clinical Oncology, vol.24, issue.34, pp.5381-5387, 2006.
DOI : 10.1200/JCO.2006.06.5391

M. Kaufmann, W. Jonat, and J. Hilfrich, Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study, Journal of Clinical Oncology, vol.25, issue.19, pp.2664-70, 2007.
DOI : 10.1200/JCO.2006.08.8054

C. Kelly and A. Buzdar, Aromatase inhibitors alone or in sequence with tamoxifen - Clinical Evaluation of the BIG 1-98 trial, Expert Opinion on Pharmacotherapy, vol.365, issue.3, pp.489-492, 2010.
DOI : 10.1001/jama.2009.1420

P. Kenemans, N. Bundred, and J. Foidart, Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial, The Lancet Oncology, vol.10, issue.2, pp.135-146, 2009.
DOI : 10.1016/S1470-2045(08)70341-3

A. Keshaviah, A. Coates, and H. Mouridsen, A comparison of letrozole compared and tamoxifen in postmenopausal women with early breast cancer, N Engl J Med, vol.353, pp.2747-2757, 2005.

L. Kligman and J. Younus, Management of hot flashes in women with breast cancer??, Current Oncology, vol.17, issue.1, pp.81-86, 2010.
DOI : 10.3747/co.v17i1.473

B. Komm, C. Terpening, and D. Benz, Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells, Science, vol.241, issue.4861, pp.81-84, 1988.
DOI : 10.1126/science.3164526

E. Krishnan, T. Sokka, A. Häkkinen, H. Hubert, and P. Hannonen, Normative values for the Health Assessment Questionnaire Disability Index: Benchmarking disability in the general population, Arthritis & Rheumatism, vol.5, issue.3, pp.953-960, 2004.
DOI : 10.1186/ar750

A. Lacassagne, Hormonal Pathogenesis of Adenocarcinoma of the Breast, The American Journal of Cancer, vol.27, issue.2, pp.217-228, 1936.
DOI : 10.1158/ajc.1936.217

B. Laurent and M. Navez, Comprendre la mémorisation de la douleur, Oxymag, vol.23, pp.4-8, 2010.

M. Lee, K. Kim, S. Choi, and E. Ernt, Acupuncture for treating hot flashes in breast cancer patients: a systematic review, Breast Cancer Research and Treatment, vol.53, issue.3, pp.497-503, 2009.
DOI : 10.1016/j.ijrobp.2008.06.1000

H. Lerner, P. Band, L. Israel, and B. Leung, Phase II study of tamoxifen: report of 74 patients with stage IV breast cancer, Cancer Treat Rep, vol.60, pp.1431-1435, 1976.

A. Lesur, B. Cutuli, and M. Teissier, Place des inhibiteurs de l???aromatase dans le cancer du sein de la femme m??nopaus??e, en situation adjuvante: les acquis et les incertitudes en 2005, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.35, issue.4, pp.327-340, 2000.
DOI : 10.1016/S0368-2315(06)76405-5

A. Lipton, H. Harvey, and R. Santen, Randomized trial of aminogluthetimide versus tamoxifen in metastatic breast cancer, Cancer Res, vol.42, pp.3434-3436, 1982.

P. Lonning, C. Pfister, and A. Martoni, Pharmacokinetics of third-generation aromatase inhibitors, Seminars in Oncology, vol.30, pp.23-32, 2003.
DOI : 10.1016/S0093-7754(03)00305-1

R. Love, D. Wiebe, J. Feyzi, P. Newcomb, and R. Chappell, Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women After 5 Years of Treatment, JNCI Journal of the National Cancer Institute, vol.86, issue.20, pp.1534-1539, 1994.
DOI : 10.1093/jnci/86.20.1534

R. Luft and H. Olivecrona, Experiences With Hypophysectomy in Man, Journal of Neurosurgery, vol.12, issue.3, pp.301-316, 1953.
DOI : 10.1210/jcem-12-4-439

M. Magliaono, Menopausal arthralgia: Fact or fiction, Maturitas, vol.67, issue.1, pp.29-33, 2010.
DOI : 10.1016/j.maturitas.2010.04.009

E. Mamounas, Adjuvant exemestane therapy after 5 years of tamoxifen : rationale for the BSABP B-33 trial, Oncology, vol.15, pp.35-39, 2001.

E. Mamounas, J. Jeong, and D. Wickerham, Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial, Journal of Clinical Oncology, vol.26, issue.12, pp.1965-1971, 2008.
DOI : 10.1200/JCO.2007.14.0228

E. Mamounas, B. Lembersky, and F. Jeong, NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor???Positive Breast Cancer, Clinical Breast Cancer, vol.7, issue.5, pp.416-421, 2006.
DOI : 10.3816/CBC.2006.n.061

A. Manni, J. Trujillo, J. Marshall, and O. Pearson, Antioestrogen-induced remissions in stage IV breast cancer, Cancer Treat Rep, vol.60, pp.1445-1450, 1976.

J. Mao, C. Stricker, and D. Bruner, Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors, Cancer, vol.1, issue.16, pp.3631-3639, 2009.
DOI : 10.1002/cncr.24419

P. Martin, M. Ferreri, and D. , le concept de qualité de vie, Nanterre : Ardix Medical, p.56, 1997.

W. Mc-guire, Estrogen Receptors in Human Breast Cancer, Journal of Clinical Investigation, vol.52, issue.1, pp.73-77, 1973.
DOI : 10.1172/JCI107175

E. Mccloskey, R. Hannon, and G. Lakner, Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women, European Journal of Cancer, vol.43, issue.17, pp.2523-2531, 2007.
DOI : 10.1016/j.ejca.2007.08.029

C. Mom, C. Buijs, P. Willemse, M. Mourits, and E. De-vries, Hot flushes in breast cancer patients, Critical Reviews in Oncology/Hematology, vol.57, issue.1, pp.63-77, 2006.
DOI : 10.1016/j.critrevonc.2005.04.009

M. Morales, N. Santana, and A. Soria, Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer, Breast Cancer Research and Treatment, vol.86, issue.3, pp.265-270, 1996.
DOI : 10.1038/bjc.1988.248

H. Mouridsen and M. Gershanovich, The role of aromatase inhibitors in the treatment of metastatic breast cancer, Seminars in Oncology, vol.30, pp.33-45, 2003.
DOI : 10.1016/S0093-7754(03)00301-4

J. Nabholtz and J. Gligorov, Cardiovascular Safety Profiles of Aromatase Inhibitors, Drug Safety, vol.23, issue.22, pp.785-801, 2006.
DOI : 10.2165/00002018-200629090-00003

M. Namer, J. Gligorov, E. Luporsi, and D. Serin, Recommandations pour la pratique clinique Saint Paul de Vence "Cancers du sein, Disponible sur, 2007.

P. Neven and H. Vernaeve, Guidelines for Monitoring Patients Taking Tamoxifen Treatment, Drug Safety, vol.53, issue.1, pp.1-11, 2000.
DOI : 10.1016/S0015-0282(16)49820-1

A. Patridge, A. Lafountain, E. Mayer, B. Taylor, E. Winer et al., Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer, Journal of Clinical Oncology, vol.26, issue.4, pp.556-562, 2008.
DOI : 10.1200/JCO.2007.11.5451

C. Pelucchi, F. Levi, and L. V. Carlo, The rise and fall in menopausal hormone therapy and breast cancer incidence, The Breast, vol.19, issue.3, pp.198-201, 2010.
DOI : 10.1016/j.breast.2010.01.021

L. Pertschuk and C. Axiotis, Steroid Hormone Receptor Immunohistochemistry in Breast Cancer: Past, Present, and Future, The Breast Journal, vol.11, issue.1, pp.3-12, 1999.
DOI : 10.1001/archsurg.1989.01410010045010

R. Peto, C. Davies, and A. Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women ? preliminary results. resented at: 30th Annual San Antonio Breast Cancer Symposium, 2007.

R. Pick, J. Stamler, S. Rodboard, and L. Katz, Estrogen-Induced Regression of Coronary Atherosclerosis in Cholesterol-Fed Chicks, Circulation, vol.6, issue.6, pp.858-861, 1952.
DOI : 10.1161/01.CIR.6.6.858

S. Polin and S. Ascher, The effect of tamoxifen on the genital tract, Cancer Imaging, vol.8, issue.1, pp.135-145, 2008.
DOI : 10.1102/1470-7330.2008.0020

C. Presant, L. Bosserman, and T. Young, Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients, Clin Cancer Update, vol.7, pp.775-778, 2007.

M. Rahman, S. Lax, and C. Sutter, CYP1B1 Is Not a Major Determinant of the Disposition of Aromatase Inhibitors in Epithelial Cells of Invasive Ductal Carcinoma, Drug Metabolism and Disposition, vol.36, issue.5, pp.963-970, 2008.
DOI : 10.1124/dmd.107.018960

A. Rat, C. Baumann, F. Guillemin, and J. Pouchot, Qualit?? de vie en rhumatologie, EMC - Appareil locomoteur, vol.5, issue.1, pp.15-908, 2010.
DOI : 10.1016/S0246-0521(10)46822-9

L. Renshaw, M. Mchugh, and L. Williams, Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole, Breast Cancer Res Treat, vol.106, pp.108-109, 2007.

A. Resch, E. Biber, M. Seifert, and H. Resch, Evidence that Tamoxifen Preserves Bone Density in Late Postmenopausal Women with Breast Cancer, Acta Oncologica, vol.61, issue.7-8, pp.661-664, 1998.
DOI : 10.1111/j.1365-2362.1988.tb02412.x

C. Ribot, F. Trémollières, and J. Pouillès, Aromatase and regulation of bone remodeling, Joint Bone Spine, vol.73, issue.1, pp.37-42, 2006.
DOI : 10.1016/j.jbspin.2005.02.005

R. Santen and H. Harvey, Use of aromatase inhibitors in breast carcinoma, Endocrine Related Cancer, vol.6, issue.1, pp.75-92, 1999.
DOI : 10.1677/erc.0.0060075

M. Savard, J. Savard, C. Quesnel, and H. Ivers, The Influence of Breast Cancer Treatment on the Occurrence of Hot Flashes, Journal of Pain and Symptom Management, vol.37, issue.4, pp.687-697, 2009.
DOI : 10.1016/j.jpainsymman.2008.04.010

A. Schinzinger, Ueber carcinoma mamma, Verh Dtsch Ces Chir, vol.18, pp.28-29, 1889.

B. Seruga and I. Tannock, Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes, Journal of Clinical Oncology, vol.27, issue.6, pp.840-842, 2009.
DOI : 10.1200/JCO.2008.19.5594

I. Sestak, J. Cuzick, and F. Sapunar, Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis, The Lancet Oncology, vol.9, issue.9, pp.866-872, 2008.
DOI : 10.1016/S1470-2045(08)70182-7

I. Smith and M. Dowsett, Aromatase Inhibitors in Breast Cancer, New England Journal of Medicine, vol.348, issue.24, pp.2431-2442, 2003.
DOI : 10.1056/NEJMra023246

M. Sprangers, Response-shift bias: a challenge to the assessment of patients' quality of life in cancer clinical trials, Cancer Treatment Reviews, vol.22, pp.55-62, 1996.
DOI : 10.1016/S0305-7372(96)90064-X

B. Stoll, Endocrine adjuvant therapy in breast cancer british medical journal, Br Med J, vol.30, p.1075, 1976.

R. Stuart-harris and A. Davis, Optimal adjuvant endocrine therapy for early breast cancer. Women's Health, Womens Health, vol.6, pp.383-398, 2010.

T. Suzuki, Y. Miki, N. Ohuchi, and H. Sasano, Intratumoral estrogen production in breast carcinoma: significance of aromatase, Breast Cancer, vol.12, issue.4, pp.270-277, 2008.
DOI : 10.1136/jcp.55.1.14

A. Swerdlow and M. Jones, Tamoxifen Treatment for Breast Cancer and Risk of Endometrial Cancer: A Case-Control Study, JNCI Journal of the National Cancer Institute, vol.346, issue.23, pp.375-384, 2005.
DOI : 10.1056/NEJM200206063462319

A. Tan and P. Emery, Role of oestrogen in the development of joint symptoms?, The Lancet Oncology, vol.9, issue.9, pp.817-818, 2008.
DOI : 10.1016/S1470-2045(08)70217-1

C. Taylor, S. Green, and W. Dalton, Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study., Journal of Clinical Oncology, vol.16, issue.3, pp.994-999, 1998.
DOI : 10.1200/JCO.1998.16.3.994

D. Toft and J. Gorski, A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization., Proceedings of the National Academy of Sciences, vol.55, issue.6, pp.1574-1581, 1966.
DOI : 10.1073/pnas.55.6.1574

M. Venturini, D. Maestro, and L. , Safety of adjuvant aromatase inhibitor therapy, Cancer Treatment Reviews, vol.32, issue.7, pp.548-556, 2006.
DOI : 10.1016/j.ctrv.2006.07.012

G. Viale, A. Giobbie-hurder, and R. M. , Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole, Journal of Clinical Oncology, vol.26, issue.34, pp.5569-5575, 2008.
DOI : 10.1200/JCO.2008.17.0829

G. Viale, M. Regan, and E. Maiorano, Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98, Journal of Clinical Oncology, vol.25, issue.25, pp.3846-3852, 2007.
DOI : 10.1200/JCO.2007.11.9453

K. Visvanathan, R. Chlebowski, and P. Hurley, American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction, Journal of Clinical Oncology, vol.27, issue.19, pp.3235-3258, 2009.
DOI : 10.1200/JCO.2008.20.5179

R. Walker, Immunohistochemical markers as predictive tools for breast cancer, Journal of Clinical Pathology, vol.61, issue.6, pp.689-696, 2008.
DOI : 10.1136/jcp.2006.041830

K. Wasan, P. Goss, and P. Pritchard, The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L), Annals of Oncology, vol.16, issue.5, pp.707-715, 2005.
DOI : 10.1093/annonc/mdi158

T. Whelan, P. Boss, and J. Ingle, Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women, Journal of Clinical Oncology, vol.23, issue.28, pp.6931-6940, 2005.
DOI : 10.1200/JCO.2005.11.181

J. Wilson and J. Jungner, Principles practise of screening for disease, Public Health Rep, vol.34, p.1, 1986.

H. Wiseman, G. Paganga, C. Rice-evans, and B. Halliwell, Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen?, Biochemical Journal, vol.292, issue.3, pp.635-638, 1993.
DOI : 10.1042/bj2920635

S. Yusuf, S. Hawken, and S. Ounpuu, Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, The Lancet, vol.364, issue.9438, pp.937-952, 2004.
DOI : 10.1016/S0140-6736(04)17018-9

J. Zidan, Z. Keidar, W. Basher, and O. Israel, Effects of Tamoxifen on Bone Mineral Density and Metabolism in Postmenopausal Women with Early-Stage Breast Cancer, Medical Oncology, vol.21, issue.2, pp.117-121, 2004.
DOI : 10.1385/MO:21:2:117